Boston Biomedical Innovation Center

波士顿生物医学创新中心

• 批准号: 8552294
• 负责人: DAVID E. GOLAN
• 金额: $ 119.47万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8552294
• 关键词: Academia; Address; Biomedical Technology; Boston; Cardiovascular system; Commit; Development; Devices; Diagnostic; Elements; Environment; Funding; Goals; Heart Diseases; Hematological Disease; Individual; Institution; Knowledge; Lung; Lung diseases; Mentors; Patients; Private Sector; Process; Public Sector; Research Infrastructure; Research Personnel; Resources; Seeds; Sleep Disorders; Societies; Staging; Technology; Therapeutic; abstracting; clinical application; commercialization; experience; innovation; new technology; skills; success; validation studies

DESCRIPTION (provided by applicant): A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of concept or validation studies essential for early stage development; insufficient access to the resources and expertise needed to develop new technologies; and a lack of knowledge and experience among academic investigators in bringing new ideas to commercial realization. Within the partnering institutions included in this application, the essential elements exist with which to build the infrastructure needed to support and sustain the uninterrupted, durable flow of inventions from discovery through development and commercialization. While these institutions have a clear track record of remarkably successful development of many biomedical technologies, most of these commercial successes have been achieved by the tenacity of individual inventors rather than with the help of committed institutional mechanisms. We proposed to address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement ("seed it"), solicitation ("find it"), and selection ("pick it") strategy; 3) efficietly and effectively bring those selected to an appropriate exit point from the development process; and 4) provide the educational and mentoring infrastructure necessary for the development of the proper entrepreneurial skills among academic innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as well as the relationship between the public and private sectors in facilitating successful development strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society. (End of Abstract)

描述（由申请人提供）： 从学术界的生物医学发现到心血管、肺、血液和睡眠疾病的治疗、设备和诊断技术的临床应用和商业化，存在着一个公认的差距。这一鸿沟是由于用于支持早期开发所必需的概念验证或验证研究的资金不足造成的；无法获得开发新技术所需的资源和专业知识；学术研究人员缺乏将新想法转化为商业实现的知识和经验。在本申请中包含的合作机构中，存在构建基础设施所需的基本要素，以支持和维持从发现到开发和商业化的不间断、持久的发明流动。虽然这些机构在许多生物医学技术的开发方面有着显着的成功记录，但大多数商业成功都是通过个人发明者的坚韧而不是在坚定的体制机制的帮助下实现的。我们建议通过建立波士顿地区心脏、肺、血液和睡眠疾病治疗、设备和诊断加速创新中心（B-BIC，或波士顿生物医学创新中心）来解决这些关键缺陷。该中心的主要目标是： 1）开发一个综合基础设施，扩大用于治疗心脏、肺、血液和睡眠障碍的商业化技术的范围； 2) 通过参与（“播种”）、征求（“找到”）和选择（“挑选”）策略，将这些机会置于适当的评估环境中； 3) 高效、有效地将那些被选中的人从开发过程中带到适当的退出点； 4）为学术创新者发展适当的创业技能提供必要的教育和指导基础设施。通过实现这些目标，B-BlC 将改变我们的学术环境文化以及公共和私营部门之间的关系，以促进心、肺、血液和睡眠障碍技术的成功开发战略，从而最终造福患者和社会。 （摘要完）